What Anti-Obesity Drugs Do Beyond Weight Loss

Following the weigh-in, the most illuminating discussions about these drugs frequently take place in a bright clinic corridor with a subtle coffee and disinfectant odor. Not while it was happening. After stepping off the scale and pulling their sleeves back down, people begin discussing strange things like waking up without experiencing that heavy, sandbag fatigue, climbing stairs without bending over, and feeling “quieter” around food in a way that’s difficult to describe without coming across as dramatic. Anti-obesity medications, particularly those in the GLP-1 family, seem to be moving away from a “weight” narrative and toward a whole-body one, which is both intriguing and a little unnerving.

The appetite has clearly changed. Attention, however, is a less evident change. A loud, continuous radio can cause cravings to fade into background static, according to some patients. That’s a practical difference in day-to-day living, not poetry. Parts of this, such as decreased appetite, a decreased preference for foods high in energy, and better control over eating, have been measured in trials; however, the lived effect may feel more social than metabolic, such as cutting back on dinnertime seconds without resorting to willpower theater. Although it’s still unclear if this mental shift is permanent or if it goes away after the novelty of a reduced appetite wears off, it has forced researchers to consider the possibility that these medications are stimulating reward circuitry in addition to stomach hormones.

The concept of “reward, not just weight” appears in contexts where medicine was previously unrelated. When once-weekly semaglutide was tested in adults with alcohol use disorder in 2025, a randomized clinical trial revealed reductions in drinking outcomes and craving signals that were significant enough to support larger trials. It’s difficult to ignore the surrounding developments as you watch this line of research develop: investors and physicians are simultaneously looking forward, spotting a new market: anti-craving medication masquerading as anti-obesity medication. Swimsuit photos may not have the greatest cultural impact of GLP-1 drugs. It could be a reinterpretation of the concept of compulsion.

Then there is the heart story, which is so direct that it has become difficult to ignore. Semaglutide (2.4 mg weekly) decreased major cardiovascular events in individuals with established cardiovascular disease and overweight or obesity, even those without diabetes, according to the SELECT trial. That endpoint—fewer heart attacks and strokes—isn’t soft and cuddly. The pessimistic view is that this just happens after losing weight. The existence of the trial and its findings, however, raises a more intriguing possibility: medications for obesity might be functioning similarly to medications for cardiovascular disease, with the scale serving as a visible side effect that promotes the benefit that cannot be seen.

Heart failure with preserved ejection fraction, a condition that can make routine tasks into minor endurance competitions, has a similar “beyond the scale” feeling. Semaglutide enhanced exercise function and alleviated physical limitations and symptoms in obese HFpEF patients in a large trial. You can see why this is important if you’ve ever witnessed someone stop at the curb and pretend to check their phone so no one can see they’re taking a breather. The medication may be restoring usable days in addition to shrinking bodies. Nonetheless, it is reasonable for skeptics to wonder how much of this is biology and how much is the mechanical comfort of weighing less. Clean separations are rare in medicine.

Since obesity, diabetes, and hypertension travel together like a bad band on tour, it seems almost inevitable that kidneys will also be discussed. According to the 2024 FLOW trial, semaglutide decreased the risk of cardiovascular death and clinically significant kidney outcomes in individuals with type 2 diabetes and chronic kidney disease. The way that clinicians think about sequencing therapies—what comes first, what protects what, and what slows the slide toward dialysis—is altered by that kind of outcome. A difficult policy question is also brought up: is a medication still “lifestyle medicine in a syringe” if it protects organs, or is it more akin to statins—boring, necessary, and underappreciated?

The change becomes almost cinematic when it comes to sleep apnea because the result is something you can visualize: fewer mornings that feel like punishment and fewer choking awakenings. The FDA approved tirzepatide (Zepbound) in December 2024 for the treatment of moderate to severe obstructive sleep apnea in obese adults. In SURMOUNT-OSA, tirzepatide decreased the apnea-hypopnea index and improved associated measures. The public’s perception of the category shifts from “weight-loss drugs” to “metabolic medicines” with several doors at this point. It also raises a practical concern: what will happen to the mask, the machine, and the entire nightly routine of CPAP if a weekly injection is effective in treating sleep apnea? It will still be necessary for some patients. Others won’t. The market will change, sometimes in a positive way.

Of course, just because the advantages increase doesn’t mean that the negative effects go away. In the real world, discontinuation is common, and nausea and constipation continue to be the unglamorous toll collectors. Additionally, there is the more ambiguous problem that doctors are avoiding: rapid weight loss can cause muscle loss, and some people appear less “healthy” even as their lab results improve. The next generation of medications may be evaluated more on how well they maintain strength, mood, and nutrition while doing so than on how quickly they move the scale.

Slowly but surely, a new form of medical bargaining is emerging. “How much will I lose?” is not the only question that patients have. “Will my blood pressure settle down?” they ask. Will I get better sleep? Will I no longer have to bargain with my knees? Will I cut back on alcohol without making a lot of effort? The truthful response is a mess: sometimes we don’t know yet, sometimes we do. However, the instructions are sufficiently explicit to alter the atmosphere in exam rooms. Nowadays, obesity is viewed as a chronic, systemic illness that doesn’t politely stay in its lane rather than as a personal failure.